Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
- Registration Number
- NCT01425411
- Lead Sponsor
- Mustafa Kemal University
- Brief Summary
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- hypertension with left ventricular hypertrophy
Exclusion Criteria
- clinical or laboratory evidence of secondary hypertension
- heart failure
- ischemic heart disease
- valvular heart disease
- arrhythmias
- peripheral vascular disease
- chronic obstructive pulmonary disease
- neurologic disorders
- diabetes mellitus
- renal dysfunction
- notable systemic disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Valsartan treatment valsartan -
- Primary Outcome Measures
Name Time Method change from baseline in midwall fractional shortening (mFS) and tissue Doppler systolic wave (Sm) measured by echocardiography at six months six months
- Secondary Outcome Measures
Name Time Method change from baseline in systolic and diastolic blood pressure at six months six months change from baseline in left ventricular mass index measured by echocardiography at six months six months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain valsartan's impact on midwall mechanics in LVH patients?
How does valsartan compare to other ARBs in improving left ventricular function in hypertension?
Are there specific biomarkers that predict valsartan response in LVH patients with hypertension?
What adverse events are associated with valsartan use in LVH patients and how are they managed?
What combination therapies with valsartan show promise for treating LVH in hypertensive patients?
Trial Locations
- Locations (1)
Mustafa Kemal University School of Medicine, Department of Cardiology
🇹🇷Antioch, Turkey
Mustafa Kemal University School of Medicine, Department of Cardiology🇹🇷Antioch, Turkey